tirzepatide weight loss clinical trial results Maintaining Loss: The Efficacy of Long-Term Therapy Lilly orforglipron oral GLP-1 phase

Among 18 studies assessing adults without mental illness, eight found GLP-1 use improved mental state and 10 studies found improvements in quality of life with GLP-1s

Developed by Eli Lilly and Company, it simultaneously targets GLP-1, GIP, and glucagon receptors a mechanism that distinguishes it from currently approved therapies such as semaglutide and tirzepatide

Both medications regulate appetite and promote fullness by activating the GLP-1 hormone, but tirzepatide takes things a step higher by also activating the GIP hormone for better results

Dates provide natural sweetness and a hint of caramel flavor

It contains semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist